Expression of imatinib mesylate-targeted kinases in endometrial carcinoma
- 31 October 2004
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 95 (1), 32-36
- https://doi.org/10.1016/j.ygyno.2004.06.052
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Uterine papillary serous carcinoma (UPSC): a single institution review of 129 casesGynecologic Oncology, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002
- STI571 (Gleevec™) as a paradigm for cancer therapyTrends in Molecular Medicine, 2002
- The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of CancerCurrent Cancer Drug Targets, 2001
- Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitorBlood, 2000
- Favorable therapeutic index of a p210 BCR-ABL -specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitorsCancer Chemotherapy and Pharmacology, 1999
- CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion ProteinsBlood, 1997
- Endometrial CarcinomaNew England Journal of Medicine, 1996
- Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cellsNature Medicine, 1996